ZNF45 Activators
ZNF45 can initiate a cascade of intracellular events leading to the protein's activation. Forskolin acts directly on adenylate cyclase, an enzyme responsible for converting ATP into cyclic AMP (cAMP), thereby increasing intracellular levels of this second messenger. The rise in cAMP triggers the activation of protein kinase A (PKA), which is known to phosphorylate various proteins, including ZNF45. Similarly, Isoproterenol operates through beta-adrenergic receptors to activate adenylate cyclase, leading to an elevation in cAMP and subsequent PKA-mediated phosphorylation of ZNF45. Prostaglandin E2 (PGE2) and Pituitary adenylate cyclase-activating peptide (PACAP-38) engage their respective G protein-coupled receptors, prompting adenylate cyclase activation, cAMP accumulation, and PKA activation, which then can phosphorylate ZNF45.
IBMX increases cAMP levels by inhibiting phosphodiesterases, which are responsible for degrading cAMP. This inhibition contributes to the activation of PKA and the sequential phosphorylation of ZNF45. Dibutyryl-cAMP, a synthetic cAMP analog, bypasses receptor-mediated activation and directly activates PKA, leading to phosphorylation of ZNF45. Cholera toxin permanently activates the Gs alpha subunit, resulting in continuous adenylate cyclase activation, increased cAMP, and sustained PKA activity, which can also phosphorylate ZNF45. Furthermore, Rolipram, by selectively inhibiting phosphodiesterase 4, prevents cAMP degradation, thereby facilitating PKA activation and subsequent phosphorylation of ZNF45. Anisomycin, though not directly linked to the cAMP pathway, is a JNK activator and may influence the phosphorylation state of ZNF45 through complex downstream signaling pathways. Lastly, L-858051, despite being a PKA inhibitor, can under specific conditions induce a conformational change in the regulatory subunits of PKA, potentially leading to ZNF45 phosphorylation, while GLP-1(7-37) activates its receptor to increase cAMP production and activate PKA, which in turn can phosphorylate ZNF45.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol acts as an agonist for beta-adrenergic receptors, leading to activation of adenylate cyclase and increased cAMP levels. The rise in cAMP activates PKA, which in turn could phosphorylate and activate ZNF45. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that break down cAMP. By preventing cAMP degradation, IBMX indirectly increases PKA activity, which may result in the phosphorylation and activation of ZNF45. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G protein-coupled receptors, leading to adenylate cyclase activation and increased cAMP levels. This signaling cascade activates PKA, which can then phosphorylate and activate ZNF45. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, triggering a G protein-coupled response that activates adenylate cyclase, thereby increasing cAMP levels and activating PKA. Activated PKA has the potential to phosphorylate and activate ZNF45. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable analog of cAMP that directly activates PKA. Once PKA is activated, it may phosphorylate target proteins such as ZNF45, leading to its activation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator that can lead to the activation of transcription factors and other proteins. This activation may extend to proteins such as ZNF45 through downstream signaling effects. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase 4 inhibitor, which prevents the breakdown of cAMP, thus leading to PKA activation. PKA activation can result in the phosphorylation and functional activation of ZNF45. | ||||||